Brief: Sangamo Therapeutics Initiates Rolling Submission Of BLA To U.S. FDA
18/12/2025 15:01
Dec 18 (Reuters) - Sangamo Therapeutics Inc SGMO.O: SANGAMO THERAPEUTICS INITIATES ROLLING SUBMISSION OF BLA TO U.S. FDA FOR ST-920 IN FABRY DISEASE SANGAMO THERAPEUTICS INC - EXPECTS TO COMPLETE BLA SUBMISSION BY Q2 2026 Source text: ID:nGNX1NhsMG Further company coverage: SGMO.O ((Reuters.Briefs@thomsonreuters.com;))